Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Conclusions In 2021, Novartis delivered mid single digit top-line growth, margin expansion, strong FCF In-market growth drivers continue to perform well across geographies, supporting our confidence in our outlook of 4%+ sales CAGR to 2026 Delivered important innovation milestones, e.g. EntrestoⓇ, 177 Lu-PSMA-617, iptacopan, Kisqali®, Leqvio® Focused on delivering on our pipeline: 20+ potential assets with significant sales for approval by 2026 Balanced capital allocation, continuing to invest in innovation alongside returning capital to our shareholder 49 Investor Relations | Q4 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation